Abilify vs Trintellix
Side-by-side cost comparison based on Medicare Part D data
Abilify
Aripiprazole
Manufactured by Otsuka/BMS
Trintellix
Vortioxetine
Manufactured by Takeda
Abilify costs 84% less per claim than Trintellix ($45.00 vs $278.00). A generic version of Abilify is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Abilify | Trintellix |
|---|---|---|
| Avg Cost Per Claim | $45.00 | $278.00 |
| Total Medicare Spending | $567.0M | $1.1B |
| Total Beneficiaries | 1,680,000 | 425,000 |
| Total Claims | 12,480,000 | 3,840,000 |
| Annual Cost/Patient | $338.00 | $2,511.00 |
| Year-over-Year Change | -38.4% | +7.8% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 30, 2026 |
| Manufacturer | Otsuka/BMS | Takeda |
| Condition | Mental Health | Mental Health |
| Generic Name | Aripiprazole | Vortioxetine |
Abilify vs Trintellix: What the Data Shows
Abilify (Aripiprazole) and Trintellix (Vortioxetine) are both used to treat mental health. Based on Medicare Part D data, Abilify costs $45.00 per claim, which is 84% less than Trintellix at $278.00 per claim.
Medicare spent $567.0M on Abilify and $1.1B on Trintellix. In terms of patient reach, Abilify serves more beneficiaries (1,680,000 vs 425,000).
Year-over-year spending changed -38.4% for Abilify and +7.8% for Trintellix.
Abilify has a generic available, while Trintellix remains brand-only until its patent expires Sep 30, 2026.
Frequently Asked Questions
Abilify is cheaper at $45.00 per claim, compared to $278.00 for Trintellix. That makes Abilify about 84% less expensive per claim based on Medicare Part D data.
Yes, both Abilify and Trintellix are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Abilify has a generic version (Aripiprazole) available, which is typically much cheaper. Trintellix is currently brand-only, with patent expiring Sep 30, 2026.
Medicare Part D spent $567.0M on Abilify covering 1,680,000 beneficiaries, and $1.1B on Trintellix covering 425,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Abilify and Trintellix on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.